Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-21-5p antagomir
- Development stage
- Preclinical
- Lead developer
- Affiliated Hospital of Guizhou Medical University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
miR-21-5p antagomir is a synthetic, chemically modified antisense oligonucleotide designed to specifically bind and inhibit microRNA-21-5p (miR-21-5p). In multiple myeloma (MM), miR-21-5p is significantly enriched in tumor-derived exosomes and acts as a key mediator of bone marrow microenvironment remodeling. By targeting the 3' untranslated region (UTR) of TGF-β1, miR-21-5p modulates the TGF-β1/SMAD signaling axis, driving the transformation of mesenchymal stem cells into cancer-associated mesenchymal stem cells (CA-MSCs). These CA-MSCs subsequently promote osteolysis and confer resistance to proteasome inhibitors like bortezomib through the secretion of CXCL12 and RANKL. Treatment with miR-21-5p antagomir, particularly when delivered via liposomal formulations, has demonstrated the ability to reverse these pathological changes, restore drug sensitivity, and reduce bone destruction in preclinical models of multiple myeloma.
- Other names
- antagomiR-21-5pantagomiR21-5pantagomiR 21-5panti-miR-21-5panti-miR21-5panti-miR 21-5p
Beyond the preview
Go deeper on miR-21-5p antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-21-5p antagomir.